Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, the company expects net product revenue of between $2.8 and $2.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 USD | -0.83% |
|
+2.56% | -88.96% |
01/07 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index | CI |
01/07 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index | CI |
1st Jan change | Capi. | |
---|---|---|
-88.96% | 65.92M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |